Lavaca Capital’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $472K | Buy |
2,169
+384
| +22% | +$85.2K | 0.08% | 71 |
|
|
2025
Q4 | $408K | Hold |
1,785
| – | – | 0.07% | 71 |
|
|
2025
Q3 | $413K | Sell |
1,785
-2,210
| -55% | -$450K | 0.07% | 68 |
|
|
2025
Q2 | $742K | Buy |
3,995
+219
| +6% | +$40.7K | 0.28% | 52 |
|
|
2025
Q1 | $791K | Sell |
3,776
-248
| -6% | -$48.2K | 0.33% | 49 |
|
|
2024
Q4 | $715K | Buy |
4,024
+286
| +8% | +$52.6K | 0.28% | 57 |
|
|
2024
Q3 | $738K | Sell |
3,738
-3,883
| -51% | -$725K | 0.31% | 51 |
|
|
2024
Q2 | $1.31M | Buy |
7,621
+20
| +0.3% | +$3.31K | 0.67% | 23 |
|
|
2024
Q1 | $1.38M | Buy |
7,601
+1,396
| +22% | +$241K | 0.81% | 20 |
|
|
2023
Q4 | $962K | Sell |
6,205
-2,922
| -32% | -$426K | 0.55% | 32 |
|
|
2023
Q3 | $1.36M | Sell |
9,127
-1,772
| -16% | -$260K | 0.46% | 44 |
|
|
2023
Q2 | $1.47M | Sell |
10,899
-8,437
| -44% | -$1.24M | 0.43% | 46 |
|
|
2023
Q1 | $2.94M | Sell |
19,336
-1,277
| -6% | -$195K | 0.62% | 28 |
|
|
2022
Q4 | $3.12M | Sell |
20,613
-181
| -0.9% | -$27.8K | 0.97% | 25 |
|
|
2022
Q3 | $2.92M | Sell |
20,794
-5,227
| -20% | -$750K | 1.05% | 21 |
|
|
2022
Q2 | $3.89M | Buy |
26,021
+247
| +1% | +$37.7K | 0.58% | 18 |
|
|
2022
Q1 | $4.18M | Sell |
25,774
-31,609
| -55% | -$4.59M | 0.45% | 25 |
|
|
2021
Q4 | $7.77M | Sell |
57,383
-8,079
| -12% | -$954K | 1% | 10 |
|
|
2021
Q3 | $7.06M | Sell |
65,462
-10,387
| -14% | -$1.19M | 0.71% | 10 |
|
|
2021
Q2 | $8.54M | Buy |
75,849
+6,610
| +10% | +$744K | 0.85% | 9 |
|
|
2021
Q1 | $7.49M | Buy |
69,239
+7,290
| +12% | +$780K | 0.64% | 10 |
|
|
2020
Q4 | $6.64M | Buy |
61,949
+1,000
| +2% | +$96.1K | 0.87% | 10 |
|
|
2020
Q3 | $5.34M | Buy |
60,949
+6,896
| +13% | +$649K | 0.84% | 15 |
|
|
2020
Q2 | $5.31M | Buy |
54,053
+908
| +2% | +$79.9K | 1.69% | 9 |
|
|
2020
Q1 | $4.05M | Buy |
53,145
+161
| +0.3% | +$13.7K | 3.92% | 8 |
|
|
2019
Q4 | $4.69M | Hold |
52,984
| – | – | 3.61% | 8 |
|
|
2019
Q3 | $4.01M | Buy |
52,984
+3,580
| +7% | +$245K | 3.03% | 8 |
|
|
2019
Q2 | $3.59M | Buy |
49,404
+20,213
| +69% | +$1.59M | 2.77% | 9 |
|
|
2019
Q1 | $2.35M | Buy |
29,191
+4,319
| +17% | +$353K | 2.01% | 14 |
|
|
2018
Q4 | $2.29M | Buy |
+24,872
| New | +$2.19M | 2.28% | 13 |
|
Other funds holding ABBV
VCM
VPM
Lavaca Capital's ABBV Position: Q1 2026 in Review
Lavaca Capital increased its AbbVie (ABBV) stake by 22% in Q1 2026, buying an estimated $85.2K and bringing the position to 2,169 shares worth $472K. The position accounts for 0.08% of the portfolio, ranked #71.
Lavaca Capital first reported a position in ABBV in Q4 2018 and has held it in 30 quarters since. The position peaked at $8.54M in Q2 2021. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- Lavaca Capital held 2,169 shares of AbbVie worth $472K as of Q1 2026.
- Lavaca Capital bought 384 AbbVie shares in Q1 2026, an estimated $85.2K.
- AbbVie made up 0.08% of Lavaca Capital's portfolio in Q1 2026, its #71 holding.
- Lavaca Capital first reported a position in AbbVie in Q4 2018 and has held it in 30 quarters since.
- Lavaca Capital's AbbVie position peaked at $8.54M in Q2 2021.
- 4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on Lavaca Capital's 13F filing for Q1 2026, filed 13 May 2026.